Return to Article Index |
| Scripps research scientists take step in stem cell work |
| Scripps Press Release |
| 10/18/2009 |
| "Dr. Zalman found this interesting and asked us to post it - let us know what you think at info@CVDF.org" *** A team led by scientists from The Scripps Research Institute has developed a method that dramatically improves the efficiency of creating stem cells from human adult tissue, without the use of embryonic cells. The research makes great strides in addressing a major practical challenge in the development of stem-cell-based medicine. The findings were published in an advance, online issue of the journal Nature Methods on Sunday. The new technique, which uses three small drug-like chemicals, is 200 times more efficient and twice as fast as conventional methods for transforming adult human cells into stem cells (in this case called "induced pluripotent stem cells" or "iPS cells"). *** In addition to its significant practical advantages, the development of the technique deepens the understanding of the biology behind the transformation of adult human cells into stem cells. The hope of most researchers in the field is that one day it will be possible to use stem cells - which possess the ability to develop into many other distinct cell types, such as nerve, heart, or lung cells - to repair damaged tissue from any number of diseases, from Type 1 diabetes to Parkinson's disease, as well as from injuries. The creation of iPS cells from adult cells sidesteps ethical concerns associated with the use of embryonic stem cells, and allows the generation of stem cells matched to a patient's own immune system, avoiding the problem of tissue rejection. *** In addition to its virtues of speed and efficiency, Ding emphasizes that the safety profile of the new method is highly promising. Not only is the method based on natural biological processes, he said, but also the type of molecules used have all been tested in humans. In addition to Ding, the article, "A Chemical Platform for Improved Induction of Human iPS Cells," was authored by Tongxiang Lin (first author), Rajesh Ambasudhan, Xu Yuan1, Wenlin Li, Simon Hilcove, Ramzey Abujarour, Xiangyi Lin, and Heung Sik Hahm of Scripps Research, and Ergeng Hao and Alberto Hayek of The Whittier Institute for Diabetes, University of California San Diego. The research was supported by the National Institutes of Health and Fate Therapeutics. To view complete article go to: http://www.carmelvalleyleader.com/news/261800-scripps-research-scientists-take-step-in-stem-cell-work |
| Additional Information: ## |